Breast cancer drug enhertu under the microscope: why do patients stop treatment?
NCT ID NCT06386263
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This completed study observed 22 adults with HER2-positive or HER2-low metastatic breast cancer who were taking trastuzumab deruxtecan (Enhertu) as part of routine care. Researchers tracked how many patients stopped treatment early or needed dose changes, and why. The goal is to provide real-world insights beyond clinical trials to help guide treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- trastuzumab deruxtecan (Enhertu)
- What this could lead to
- If successful, this study could help doctors and patients better understand how well trastuzumab deruxtecan works in everyday practice and why some people stop treatment.
- What could go wrong
- This is a small, completed observational study (22 people) that looks back at existing data, so it cannot prove cause and effect or predict outcomes for new patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-LOW EXPRESSING BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Oakville, Ontario, L6H1A7, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer